A
BMRN icon

AlphaQuest’s BioMarin Pharmaceuticals BMRN Stock Holding History

AlphaQuest’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,645
Closed -$157K – 286
2025
Q4 		$157K Sell
2,645
-10,815
-80% -$589K 0.01% 1551
2025
Q3 		$729K Sell
13,460
-21,696
-62% -$1.24M 0.05% 581
2025
Q2 		$1.93M Buy
35,156
+9,895
+39% +$583K 0.19% 92
2025
Q1 		$1.79M Buy
25,261
+14,950
+145% +$1.01M 0.19% 129
2024
Q4 		$678K Buy
10,311
+5,975
+138% +$400K 0.09% 361
2024
Q3 		$305K Buy
+4,336
New +$362K 0.03% 894
2024
Q2 		– Sell
-16,134
Closed -$1.41M – 1600
2024
Q1 		$1.41M Buy
+16,134
New +$1.44M 0.25% 127

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AlphaQuest's BMRN Position: Q1 2026 in Review

AlphaQuest sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 2,645 shares — an estimated $157K sold.

AlphaQuest first reported a position in BMRN in Q1 2024 and held it in 7 quarters. The position peaked at $1.93M in Q2 2025. 559 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • AlphaQuest reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 2,645 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $157K.
  • AlphaQuest first reported a position in BioMarin Pharmaceuticals in Q1 2024 and held it in 7 quarters.
  • AlphaQuest's BioMarin Pharmaceuticals position peaked at $1.93M in Q2 2025.
  • 559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.